Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo Controlled Trial of Aldafermin (NGM282) for Treatment of Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

NCT05130047 is registered in ClinicalTrials.gov with Michael Camilleri, MD as lead sponsor.

NCT NCT05130047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05130047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo Controlled Trial of Aldafermin (NGM282) for Treatment of Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)
Lead sponsor
Michael Camilleri, MD
Phase
Phase 2
Overall status
Completed
Start date
December 1, 2021
Completion date
November 8, 2022
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bile acid diarrhea, bile acid malabsorption, bile acid malabsorption syndrome type ii, chronic diarrhea, functional diarrhea, irritable bowel syndrome with diarrhea